stocks logo

NTLA

Intellia Therapeutics Inc
$
12.500
-0.61(-4.653%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.190
Open
13.190
VWAP
--
Vol
4.90M
Mkt Cap
1.29B
Low
12.280
Amount
--
EV/EBITDA(TTM)
--
Total Shares
96.48M
EV
791.05M
EV/OCF(TTM)
--
P/S(TTM)
27.66
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
14.58M
+13.26%
-0.963
-24.19%
12.41M
+36.2%
-0.978
-27%
12.26M
+76.22%
-1.008
-33.65%
Estimates Revision
The market is revising Upward the revenue expectations for Intellia Therapeutics, Inc. (NTLA) for FY2025, with the revenue forecasts being adjusted by 13.75% over the past three months. During the same period, the stock price has changed by 40.92%.
Revenue Estimates for FY2025
Revise Upward
up Image
+13.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-9.61%
In Past 3 Month
Stock Price
Go Up
up Image
+40.92%
In Past 3 Month
22 Analyst Rating
up Image
134.80% Upside
Wall Street analysts forecast NTLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTLA is 29.35 USD with a low forecast of 7.00 USD and a high forecast of 65.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
4 Hold
1 Sell
Moderate Buy
up Image
134.80% Upside
Current: 12.500
sliders
Low
7.00
Averages
29.35
High
65.00
Canaccord
Buy
maintain
$74 -> $54
2025-06-03
Reason
Canaccord lowered the firm's price target on Intellia Therapeutics to $54 from $74 and keeps a Buy rating on the shares. The target reduction comes following its update from its ongoing Ph3 studies. The main takeaway is that things are *mostly* on track. Newly updated / slightly delayed is progress with the MAGNITUDE study of nex-z for ATTR-CM - the company has enrolled about 48% of the target number of patients so far though now plans to complete enrollment by early 2027 versus YE26 previously.
BofA
Buy
downgrade
$43 -> $39
2025-05-29
Reason
BofA lowered the firm's price target on Intellia Therapeutics to $39 from $43 and keeps a Buy rating on the shares after the company reported a single grade 4 liver transaminase elevation in the phase 3 MAGNITUDE study for nex-z in transthyretin amyloid cardiomyopathy. Despite the relatively clean profile before today, the firm expects a safety overhang for the program until further data is available, the analyst tells investors. The firm still sees potential for a one-time treatment option in hereditary angioedema and ATTR markets, but lowers its view of the probability of success in ATTR-CM to 30% from 35% pending additional safety follow-ups for nex-z.
Goldman Sachs
Goldman Sachs
downgrade
$8
2025-05-29
Reason
Goldman Sachs believes the grade 4 liver transaminase elevation safety event disclosed by Intellia Therapeutics for the Phase 3 MAGNITUDE study potentially places nex-z's commercial positioning further in question given the CRISPR therapy's lack of an established long-term safety profile. The therapy has shown limited differentiation on efficacy versus siRNA competitors, the analyst tells investors in a research note. Goldman has a Sell rating on Intellia with an $8 price target. The stock in morning trading is down 28%, or $2.70, to $6.96.
Guggenheim
Buy
downgrade
$55 -> $45
2025-05-12
Reason
Guggenheim lowered the firm's price target on Intellia Therapeutics to $45 from $55 and keeps a Buy rating on the shares. Competitive one-time net pricing of about $500,000 positions NTLA-2001as "a potential blockbuster, even if relegated to second line," says the analyst, who adds that meaningful readouts between now and the first half of 2027 should offer "compelling entry points" with trial enrollment ahead of schedule.
Citi
Neutral
downgrade
$14 -> $10
2025-05-09
Reason
Citi lowered the firm's price target on Intellia Therapeutics to $10 from $14 and keeps a Neutral rating on the shares. The company reported Q1 results and reiterated its plans for the coming year to focus on clinical trial execution, the analyst tells investors in a research note.
Truist
Buy
downgrade
$50 -> $33
2025-05-08
Reason
Truist lowered the firm's price target on Intellia Therapeutics to $33 from $50 and keeps a Buy rating on the shares. The company's Q1 update was notable for news that its Phase 3 HAELO trial is on track for complete enrollment in Q3, a welcome update as the firm sees clear value proposition for NTLA-2002, the analyst tells investors in a research note. The firm, however, trimmed its tech value for Intellia's platform given challenging capital markets and ongoing pipeline prioritization, which drives the price target lower.

Valuation Metrics

The current forward P/E ratio for Intellia Therapeutics Inc (NTLA.O) is -3.08, compared to its 5-year average forward P/E of -11.56. For a more detailed relative valuation and DCF analysis to assess Intellia Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.56
Current PE
-3.08
Overvalued PE
-0.61
Undervalued PE
-22.51

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.73
Current EV/EBITDA
-1.66
Overvalued EV/EBITDA
0.15
Undervalued EV/EBITDA
-17.61

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
90.67
Current PS
27.71
Overvalued PS
167.54
Undervalued PS
13.80

Financials

Annual
Quarterly
FY2025Q1
YoY :
-42.54%
16.63M
Total Revenue
FY2025Q1
YoY :
+5.97%
-120.81M
Operating Profit
FY2025Q1
YoY :
+6.42%
-114.33M
Net Income after Tax
FY2025Q1
YoY :
-1.79%
-1.10
EPS - Diluted
FY2025Q1
YoY :
+21.51%
-149.67M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+5.24%
-836.43
FCF Margin - %
FY2025Q1
YoY :
+85.19%
-687.61
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 940.21% over the last month.
Sold
0-3
Months
168.6K
USD
5
3-6
Months
8.4K
USD
2
6-9
Months
736.8K
USD
7
0-12
Months
38.3K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
233.0K
Volume
1
6-9
Months
1.1M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.0M
Volume
Months
6-9
2
1.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

NTLA News & Events

Events Timeline

2025-05-29 (ET)
2025-05-29
07:00:00
Intellia adverse event could resurface questions, says JPMorgan
select
2025-05-29
06:41:25
Intellia discloses grade 4 liver transaminase elevation in MAGNITUDE trial
select
2025-05-08 (ET)
2025-05-08
07:32:42
Intellia Therapeutics sees cash runway into 1H27
select
Sign Up For More Events

News

2.0
07-09NASDAQ.COM
Bullish Two Hundred Day Moving Average Cross - NTLA
6.5
07-08MarketWatch
Goldman Sachs lifts S&P 500 forecasts, recommends these three investment moves
9.0
07-07Benzinga
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
Sign Up For More News

FAQ

arrow icon

What is Intellia Therapeutics Inc (NTLA) stock price today?

The current price of NTLA is 12.5 USD — it has decreased -4.65 % in the last trading day.

arrow icon

What is Intellia Therapeutics Inc (NTLA)'s business?

arrow icon

What is the price predicton of NTLA Stock?

arrow icon

What is Intellia Therapeutics Inc (NTLA)'s revenue for the last quarter?

arrow icon

What is Intellia Therapeutics Inc (NTLA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Intellia Therapeutics Inc (NTLA)'s fundamentals?

arrow icon

How many employees does Intellia Therapeutics Inc (NTLA). have?

arrow icon

What is Intellia Therapeutics Inc (NTLA) market cap?